Characterization of monoclonal antibodies specific for the Merkel cell polyomavirus capsid.
Merkel cell polyomavirus (MCV) has been implicated as a causative agent in Merkel cell carcinoma. Robust polyclonal antibody responses against MCV have been documented in human subjects, but monoclonal antibodies (mAbs) specific for the VP1 capsid protein have not yet been characterized. We generated 12 mAbs capable of binding recombinant MCV virus-like particles. The use of a short immunogenic priming schedule was important for production of the mAbs. Ten of the 12 mAbs were highly effective for immunofluorescent staining of cells expressing capsid proteins. An overlapping set of 10 mAbs were able to neutralize the infectivity of MCV-based reporter vectors, with 50% effective doses in the low picomolar range. Three mAbs interfered with the binding of MCV virus-like particles to cells. This panel of anti-capsid antibodies should provide a useful set of tools for the study of MCV.
Pastrana
Diana V
DV
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892-4263, USA.
Pumphrey
Katherine A
KA
Cuburu
Nicolas
N
Schowalter
Rachel M
RM
Buck
Christopher B
CB
D000818:Animals; D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral / Q000097:blood*; D000915:Antibody Affinity; D000918:Antibody Specificity; D000956:Antigens, Viral; D036022:Capsid Proteins / Q000276:immunology*; D015266:Carcinoma, Merkel Cell / Q000821:virology; D005260:Female; D006367:HeLa Cells; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D011120:Polyomavirus / Q000276:immunology*
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D000956:Antigens, Viral; D036022:Capsid Proteins